Theravance Biopharma TBPH
TBPH
$17.03 +0.00 (+0.00%)
At close: Sep 25, 2026 · 4:00 PM EDT

Theravance Biopharma (TBPH) EV to EBITDA (2026)

Updated

Theravance Biopharma's EV to EBITDA came in at 149.99 for Q1 2026.

Analysis

Theravance Biopharma (TBPH) EV to EBITDA (2026) Analysis & Trends

Over the trailing twelve months to Mar 31, 2026, Theravance Biopharma reported EV to EBITDA of -184.31.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,138.83 Bn 1,107.41 Bn 19.71 Bn
2 Johnson & Johnson 618.88 Bn 537.41 Bn 17.26 Bn
3 AbbVie 502.93 Bn 476.04 Bn 12.70 Bn
4 Merck 369.61 Bn 323.99 Bn 12.21 Bn
5 Novartis Ag 298.70 Bn 262.69 Bn 11.24 Bn
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn
7 Amgen 237.59 Bn 192.99 Bn 7.24 Bn
8 Gilead Sciences 191.60 Bn 165.79 Bn 6.22 Bn
9 Pfizer 170.23 Bn 116.88 Bn 10.94 Bn
10 Theravance Biopharma 883.70 Mn -543.66 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 149.99
API Access

Theravance Biopharma EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=TBPH&period=max&api_key=YOUR_API_KEY